T Cell Immunotherapy for Immune Reconstitution and GVHD Prevention After Allogeneic Hematopoietic Stem Cell Transplantation

被引：1
作者：
Lucarelli B. [1 ]
Merli P. [1 ]
Strocchio L. [1 ]
Cefalo M.G. [1 ]
Brescia L.P. [1 ]
Locatelli F. [1 ,2 ]
机构：
[1] Department of Pediatric Hematology-Oncology, IRCCS, Bambino Gesù Children’s Hospital, Piazza Sant’Onofrio, Rome
[2] Department of Pediatrics, University of Pavia, Pavia
来源：
Current Stem Cell Reports | 2015年 / 1卷 / 4期
基金：
欧盟地平线“2020”;
关键词：
Donor lymphocytes infusions; Hematopoietic stem cell transplantation; Immune reconstitution; Immunotherapy; T cell;
D O I：
10.1007/s40778-015-0027-z
中图分类号：
学科分类号：
摘要：
Many different studies have demonstrated that early recovery of the adaptive immune system after allogeneic hematopoietic stem cell transplantation (HSCT) is predominantly sustained by peripheral expansion of donor-derived, mature lymphocytes transferred with the graft. Different approaches based on the infusion of donor T cells after HSCT have been developed mainly to accelerate immune recovery and to treat/prevent (a) malignancy recurrence, (b) life-threatening infections, and (c) immune-mediated disorders, such as graft-versus-host disease (GVHD). For many years, donor lymphocyte infusion (DLI) has been a widely used approach to prevent and to treat leukemia recurrence, to convert mixed chimerism into complete donor chimerism, and to accelerate immune reconstitution of patients after HSCT. More sophisticated strategies of adoptive infusion of T cell lines/clones capable of mediating a graft-versus-leukemia (GVL) response, while avoiding GVHD occurrence, or specific for the most life-threatening pathogens (e.g., cytomegalovirus, Epstein-Barr virus, and adenovirus) have been envisaged and successfully tested in pilot trials in the early post-transplantation period. Also, ex vivo expanded regulatory T (Treg) cells have been shown to be beneficial for preventing GVHD post-HSCT. In this review, we will focus on DLI as well as more complex cellular therapies that require extensive cell manipulation. © 2015, Springer International Publishing AG.
引用
收藏
页码：206 / 214
页数：8
相关论文
共 100 条
[41]  
Theurich S., Malcher J., Wennhold K., Et al., Brentuximab vedotin combined with donor lymphocyte infusions for early relapse of Hodgkin lymphoma after allogeneic stem-cell transplantation induces tumor-specific immunity and sustained clinical remission, J Clin Oncol, 31, 5, pp. e59-e63, (2013)
[42]  
Berglund S., Gertow J., Uhlin M., Et al., Expanded umbilical cord blood T cells used as donor lymphocyte infusions after umbilical cord blood transplantation, Cytotherapy, 16, 11, pp. 1528-1536, (2014)
[43]  
Ciceri F., Bonini C., Gallo-Stampino C., Et al., Modulation of GvHD by suicide-gene transduced donor T lymphocytes: clinical applications in mismatched transplantation, Cytotherapy, 7, 2, pp. 144-149, (2005)
[44]  
Bonini C., Ferrari G., Verzeletti S., Et al., HSV-TK gene transfer into donor lymphocytes for control of allogeneic graft-versus-leukemia, Science, 276, 5319, pp. 1719-1724, (1997)
[45]  
Ciceri F., Bonini C., Marktel S., Et al., Antitumor effects of HSV-TK-engineered donor lymphocytes after allogeneic stem-cell transplantation, Blood, 109, 11, pp. 4698-4707, (2007)
[46]  
Ciceri F., Bonini C., Stanghellini M.T., Et al., Infusion of suicide-gene-engineered donor lymphocytes after family haploidentical haemopoietic stem-cell transplantation for leukaemia (the TK007 trial): a non-randomised phase I-II study, Lancet Oncol, 10, 5, pp. 489-500, (2009)
[47]  
Di Stasi A., Tey S.K., Dotti G., Et al., Inducible apoptosis as a safety switch for adoptive cell therapy, N Engl J Med, 365, 18, pp. 1673-1683, (2011)
[48]  
Zhou X., Di Stasi A., Tey S.K., Et al., Long-term outcome after haploidentical stem cell transplant and infusion of T cells expressing the inducible caspase 9 safety transgene, Blood, 123, 25, pp. 3895-3905, (2014)
[49]  
Zhou X., Dotti G., Krance R.A., Inducible caspase-9 suicide gene controls adverse effects from alloreplete T cells after haploidentical stem cell transplantation, Blood, (2015)
[50]  
Traversari C., Marktel S., Magnani Z., Et al., The potential immunogenicity of the TK suicide gene does not prevent full clinical benefit associated with the use of TK-transduced donor lymphocytes in HSCT for hematologic malignancies, Blood, 109, 11, pp. 4708-4715, (2007)
12345678910